These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23434231)

  • 1. Emerging therapies for postmenopausal vaginal atrophy.
    Pickar JH
    Maturitas; 2013 May; 75(1):3-6. PubMed ID: 23434231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
    Pinkerton JV; Stanczyk FZ
    Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Local estrogen therapy--clinical implications--2012 update].
    Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
    Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy.
    Rees M; Pérez-López FR; Ceasu I; Depypere H; Erel T; Lambrinoudaki I; Schenck-Gustafsson K; Simoncini T; van der Schouw Y; Tremollieres F;
    Maturitas; 2012 Oct; 73(2):171-4. PubMed ID: 22818886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
    Tan O; Bradshaw K; Carr BR
    Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and prospects in treating postmenopausal vaginal atrophy.
    Winneker RC; Harris HA
    Clin Pharmacol Ther; 2011 Jan; 89(1):129-32. PubMed ID: 20944561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of raloxifene on sexual function in postmenopausal women.
    Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
    Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective estrogen receptor modulators and vulvovaginal atrophy: can we improve the lives of our patients with new therapeutic options?
    Shulman LP
    Menopause; 2010; 17(3):452-3. PubMed ID: 20464782
    [No Abstract]   [Full Text] [Related]  

  • 12. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
    Gennari L
    Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA; Komi JO;
    Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
    Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
    Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
    Al-Baghdadi O; Ewies AA
    Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
    DeGregorio MW; Zerbe RL; Wurz GT
    Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women.
    Goldstein I; Alexander JL
    J Sex Med; 2005 Sep; 2 Suppl 3():154-65. PubMed ID: 16422792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
    North American Menopause Society
    Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners.
    Simon JA; Nappi RE; Kingsberg SA; Maamari R; Brown V
    Menopause; 2014 Feb; 21(2):137-42. PubMed ID: 23736862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.
    Cano A; Estévez J; Usandizaga R; Gallo JL; Guinot M; Delgado JL; Castellanos E; Moral E; Nieto C; del Prado JM; Ferrer J
    Menopause; 2012 Oct; 19(10):1130-9. PubMed ID: 22914208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.